HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
17 hedge funds and large institutions have $4.18M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 7 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
30% more capital invested
Capital invested by funds: $3.22M → $4.18M (+$956K)
19% less funds holding
Funds holding: 21 → 17 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWP
Private Wealth Partners
Mill Valley,
California
|
+$742K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$205K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$129K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$111K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$85.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$332K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$122K |
| 3 |
VF
Virtu Financial
New York
|
-$107K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$56K |
| 5 |
Bank of New York Mellon
New York
|
-$53K |
HTGM Hedge Fund Activity: Q4 2017 in Review
17 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2017, worth a combined $4.18M — up 30% from $3.22M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of HTGM and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Private Wealth Partners, opening a new position worth an estimated $742K. The largest seller was Laurion Capital Management, exiting entirely with an estimated $332K sold.
- 17 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2017, down from 21 in Q3 2017.
- Funds reported $4.18M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2017, up 30% quarter-over-quarter.
- 3 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2017 and 7 closed out, a net change of -4 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2017 was Private Wealth Partners, an estimated $742K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2017 was Laurion Capital Management, an estimated $332K sold.
Based on aggregated 13F filings for Q4 2017.